Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab, Bevacizumab, and Niraparib in Platinum-Resistant Ovarian Cancer (OPAL Cohort A)
NCT05751629Phase 2Completed
- Start
- Nov 2018
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC). Started Nov 2018; status: completed.
02
Drugs
dostarlimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05751629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751629.